GenSight Biologics SA 2020 IR
The report highlights GenSight Biologics' progress in 2020, including the submission of the Marketing Authorization Application (MAA) for its lead product LUMEVOQ® to the European Medicines Agency (EMA). The company also advanced its second product candidate, GS030, in the PIONEER Phase I/II clinical trial. Financially, GenSight raised €25 million in a private placement and secured a €6.75 million state-guaranteed loan to support its operations. The company began generating initial revenues from the sale of LUMEVOQ® under Temporary Authorizations for Use (ATU) in France.
Company: GenSight Biologics SA
Sector: Professional & technical services
Country: France
Year: 2020
Type: IR
Pages: 300
Back to company
GenSight Biologics SA
Universal Registration Document
The report highlights GenSight Biologics' progress in 2020, including the submission of the Marketing Authorization Application (MAA) for its lead product LUMEVOQ® to the European Medicines Agency (EMA). The company also advanced its second product candidate, GS030, in the PIONEER Phase I/II clinical trial. Financially, GenSight raised €25 million in a private placement and secured a €6.75 million state-guaranteed loan to support its operations. The company began generating initial revenues from the sale of LUMEVOQ® under Temporary Authorizations for Use (ATU) in France.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Published
Apr 8, 2021
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees